Приказ основних података о документу

Određivanje anizomicina tečnom hromatografijom sa tandem masenom spektrometrijom i elektrohemijskim metodama i primena na ispitivanje stabilnosti leka i njegove raspodele u tkivima pacova

dc.contributor.advisorLaušević, Mila
dc.contributor.otherGrujić, Svetlana
dc.contributor.otherPetrović, Slobodan
dc.contributor.otherRažić, Slavica
dc.contributor.otherMiljković, Branislava
dc.creatorTolić, Ljiljana
dc.date.accessioned2021-03-10T15:15:12Z
dc.date.available2021-03-10T15:15:12Z
dc.date.issued2018
dc.identifier.urihttp://eteze.bg.ac.rs/application/showtheses?thesesId=5745
dc.identifier.urihttps://fedorabg.bg.ac.rs/fedora/get/o:17567/bdef:Content/download
dc.identifier.urihttp://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=50003215
dc.identifier.urihttp://TechnoRep.tmf.bg.ac.rs/handle/123456789/4670
dc.description.abstractDrug anisomycin is a potential immunosuppressant in low doses (≤ 0.1 μM). It also has the potential use as a psychopharmaceutical and an anticancerous drug, and in the recent investigations it was shown that it is a potential radioprotector. Despite of multiple potential applications of anisomysin, its clinical use has not been reported yet. In that order, it is necessary to understand the pharmacokinetic properties of the drug, primarily its body distribution and the most important pharmacokinetic parameters. Also, in order to establish quality of the drug and safety of its use, it is required to monitor its stability and to determine its degradation products that may be formed during production, handling or storage...en
dc.description.abstractLek anizomicin je potencijalni imunosupresor pri niskim dozama (≤ 0,1 μM). TakoĎe ima potencijalnu primenu kao psihofarmaceutik i antikancerogeni lek, a u novijim istraţivanjima se pokazalo da je potencijalni radioprotektor. I pored višestruke potencijalne primene anizomicina, još uvek nema podataka o njegovoj kliničkoj primeni. Zbog toga je potrebno poznavanje farmakokinetičkih svojstava leka, pre svega poznavanje principa raspodele leka u organizmu i najznačajnijih farmakokinetičkih parametara. TakoĎe, da bi se utvrdio kvalitet leka i bezbednost njegovog korišćenja, potrebno je pratiti stabilnost i odrediti degradacione proizvode koji mogu nastati tokom proizvodnje, rukovanja ili čuvanja leka...sr
dc.publisherUniverzitet u Beogradu, Tehnološko-metalurški fakultet
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172007/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectanisomycinen
dc.subjectliquid chromatographyen
dc.subjectelectrochemical methodsen
dc.subjectbiological materialen
dc.subjecttissue distribution of the drugen
dc.subjectpharmacokinetic parametersen
dc.subjectforced degradationen
dc.subjecttandem mass spectrometryen
dc.subjectanizomicinsr
dc.subjecttečna hromatografijasr
dc.subjectelektrohemijske metodesr
dc.subjectbiološki materijalsr
dc.subjectraspodela leka u tkivimasr
dc.subjectfarmakokinetički parametrisr
dc.subjectforsirana degradacijasr
dc.subjecttandem masena spektrometrijasr
dc.titleDetermination of anisomycin by liquid chromatography with tandem mass spectrometry and electrochemical methods and application to investigation of drug stability and its distribution in rat tissuesen
dc.titleOdređivanje anizomicina tečnom hromatografijom sa tandem masenom spektrometrijom i elektrohemijskim metodama i primena na ispitivanje stabilnosti leka i njegove raspodele u tkivima pacovasr
dc.typedoctoralThesis
dc.rights.licenseBY-NC-ND
dc.identifier.fulltexthttp://TechnoRep.tmf.bg.ac.rs/bitstream/id/2197/4667.pdf
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_technorep_4670
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу